Roberto Cerrud-Rodriguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roberto Cerrud-Rodriguez has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Luigi Di Biase
Montefiore Einstein Center for Heart and Vascular Care, Montefiore Medical Center , Bronx, NY, 10467
4 shared publications Katerina Jou
SBH Health System, Department of Internal Medicine City University of New York School of Medicine Bronx New York USA
2 shared publicationsKhaled Elfert
SBH Health System, Department of Internal Medicine City University of New York School of Medicine Bronx New York USA
2 shared publicationsMario J. Garcia
Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York
2 shared publicationsMushrin Malik
SBH Health System, Department of Internal Medicine City University of New York School of Medicine Bronx New York USA
2 shared publications- Nelson Barrera
Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, New York, USA
2 shared publications
Latest Publications
- 3 November 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (1) , 103-110
Safety of catheter ablation for atrial fibrillation in patients with liver cirrhosis
Background and Aims: Atrial fibrillation is the most prevalent cardiac arrhythmia, and catheter ablation (CA) has emerged as a viable treatment option for selected patients. However, its safety profile in liver cirrhosis (LC) populations remains underexplored.Methods: This was an observational analysis of the National Inpatient Sample Database 2016–2020; we analyzed adult encounters undergoing CA for atrial fibrillation who had a concomitant diagnosis of LC. Using propensity scores, encounters were divided into two cohorts based on the presence or absence of LC and matched in a 1:1 fashion using LC as the dependent variable. In‐hospital mortality and postprocedure total complications were compared using regression models.Results: 93 830 procedures were identified for non‐LC patients and 960 involving LC patients; after propensity score matching, each cohort included 910 hospitalizations. The mean age in the LC‐matched cohort was 66.5 ± 9.1 years. In‐hospital mortality did not differ between the groups (aOR = 1.01; 95% CI [0.06–16.1]; p = .99). However, the LC cohort exhibited higher odds of total complications (aOR = 1.98; 95% CI [1.42–2.75]; p < .001). Length of stay (LOS) was comparable, but total costs were higher in the LC cohort: LOS was 2 days (95% CI [1–3]) in the LC group versus 3 days (95% CI [1–4]) (p < .11) and LC: $202,000 (95% CI [$142 000–$261 000]) versus non‐LC: $189 000, (95% CI [$153 000–$222 000]) (p < .0001).Conclusion: In this national analysis of patients undergoing CA for AF, those with LC had similar in‐hospital mortality, postprocedure complications, and LOS compared to noncirrhotic patients. Furthermore, longitudinal studies are needed to assess the safety profile of CA in this subpopulation.
- 3 November 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (1) , 103-110
Safety of catheter ablation for atrial fibrillation in patients with liver cirrhosis
Background and Aims: Atrial fibrillation is the most prevalent cardiac arrhythmia, and catheter ablation (CA) has emerged as a viable treatment option for selected patients. However, its safety profile in liver cirrhosis (LC) populations remains underexplored.Methods: This was an observational analysis of the National Inpatient Sample Database 2016–2020; we analyzed adult encounters undergoing CA for atrial fibrillation who had a concomitant diagnosis of LC. Using propensity scores, encounters were divided into two cohorts based on the presence or absence of LC and matched in a 1:1 fashion using LC as the dependent variable. In‐hospital mortality and postprocedure total complications were compared using regression models.Results: 93 830 procedures were identified for non‐LC patients and 960 involving LC patients; after propensity score matching, each cohort included 910 hospitalizations. The mean age in the LC‐matched cohort was 66.5 ± 9.1 years. In‐hospital mortality did not differ between the groups (aOR = 1.01; 95% CI [0.06–16.1]; p = .99). However, the LC cohort exhibited higher odds of total complications (aOR = 1.98; 95% CI [1.42–2.75]; p < .001). Length of stay (LOS) was comparable, but total costs were higher in the LC cohort: LOS was 2 days (95% CI [1–3]) in the LC group versus 3 days (95% CI [1–4]) (p < .11) and LC: $202,000 (95% CI [$142 000–$261 000]) versus non‐LC: $189 000, (95% CI [$153 000–$222 000]) (p < .0001).Conclusion: In this national analysis of patients undergoing CA for AF, those with LC had similar in‐hospital mortality, postprocedure complications, and LOS compared to noncirrhotic patients. Furthermore, longitudinal studies are needed to assess the safety profile of CA in this subpopulation.
- Open Access
- 21 July 2024
- Published by Wiley
Safety of Catheter Ablation for Atrial Fibrillation in Patients with Liver Cirrhosis
Background and Aims Atrial fibrillation is the most prevalent cardiac arrhythmia, and catheter ablation (CA) has emerged as a viable option for selected patients. However, its role in specific liver cirrhosis (LC) populations remains underexplored. Methods Using the National Inpatient Sample Database 2016–2020, we analyzed adult encounters undergoing CA for atrial fibrillation diagnosed with LC. Using propensity scores, encounters were divided into 2 cohorts based on the presence and absence of LC and matched in a 1:1 fashion using LC as the dependent variable. In-hospital mortality and post-procedure total complications were compared using logistic regression models and linear regression for length of stay and total cost of hospitalization. Results We identified 93,830 atrial fibrillation CA admissions, of which 910 had LC. The mean age in the LC cohort was 66.5±5.1 years. Mortality did not significantly differ between the groups (aOR=0.85; 95%CI=0.28-2.60; P =0.77). However, the LC cohort exhibited higher odds of total complications (aOR=2.00; 95%CI=1.11-3.48; pP P Conclusion In the 2016-2020 National Inpatient Sample, patients who underwent atrial fibrillation CA with LC, mortality, and length of stay were comparable. However, the likelihood of total complications was higher to a propensity score‐matched cohort of no cirrhotics patients. Further, longitudinal studies are needed it to assess the safety profile of CA in this sub-population
- 21 July 2024
- Published by Wiley
Open AccessSafety of Catheter Ablation for Atrial Fibrillation in Patients with Liver Cirrhosis
Background and Aims Atrial fibrillation is the most prevalent cardiac arrhythmia, and catheter ablation (CA) has emerged as a viable option for selected patients. However, its role in specific liver cirrhosis (LC) populations remains underexplored. Methods Using the National Inpatient Sample Database 2016–2020, we analyzed adult encounters undergoing CA for atrial fibrillation diagnosed with LC. Using propensity scores, encounters were divided into 2 cohorts based on the presence and absence of LC and matched in a 1:1 fashion using LC as the dependent variable. In-hospital mortality and post-procedure total complications were compared using logistic regression models and linear regression for length of stay and total cost of hospitalization. Results We identified 93,830 atrial fibrillation CA admissions, of which 910 had LC. The mean age in the LC cohort was 66.5±5.1 years. Mortality did not significantly differ between the groups (aOR=0.85; 95%CI=0.28-2.60; P =0.77). However, the LC cohort exhibited higher odds of total complications (aOR=2.00; 95%CI=1.11-3.48; pP P Conclusion In the 2016-2020 National Inpatient Sample, patients who underwent atrial fibrillation CA with LC, mortality, and length of stay were comparable. However, the likelihood of total complications was higher to a propensity score‐matched cohort of no cirrhotics patients. Further, longitudinal studies are needed it to assess the safety profile of CA in this sub-population
- 10 May 2024
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 80 (3) , 780-790.e10
Impact of early intervention on health status outcomes in peripheral artery disease patients with chronic total occlusion lesions using the PORTRAIT registry
- 10 May 2024
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 80 (3) , 780-790.e10
Impact of early intervention on health status outcomes in peripheral artery disease patients with chronic total occlusion lesions using the PORTRAIT registry
- Open Access
- 16 June 2023
- Published by Springer Nature in Cureus
- Vol. 15 (6) , e40514
Swimming With Sharks: Left Main Coronary Obstruction Following Transcatheter Aortic Valve Implantation
Delayed coronary obstruction (DCO) occurs when there is obstruction of the coronary ostia following a transcatheter aortic valvular implantation (TAVI). It is an uncommon but serious complication that often leads to death, usually presents as severe hypotension after TAVI, and should be suspected if migration of the valve occurs. We report the case of a 70-year-old female patient with severe aortic stenosis who underwent TAVI using a 26-mm CoreValve Evolut Pro (Medtronic, Dublin, Ireland). Although the valve was implanted successfully, she experienced hypotension with intermittent ST elevations and had a cardiac arrest shortly after, requiring Advanced Cardiovascular Life Support (ACLS). An aortogram showed sealing of the sinotubular junction (STJ) by CoreValve, without coronary flow. CoreValve was then snared and repositioned in the ascending aorta recovering coronary flow and cardiac pulsatility. A second TAVI was performed and an Edwards 20 mm Sapiens 3 valve (Edwards Lifesciences, Irvine, CA, USA) was implanted as standard procedure.
- 16 June 2023
- Published by Springer Nature in Cureus
- Vol. 15 (6) , e40514
Open AccessSwimming With Sharks: Left Main Coronary Obstruction Following Transcatheter Aortic Valve Implantation
Delayed coronary obstruction (DCO) occurs when there is obstruction of the coronary ostia following a transcatheter aortic valvular implantation (TAVI). It is an uncommon but serious complication that often leads to death, usually presents as severe hypotension after TAVI, and should be suspected if migration of the valve occurs. We report the case of a 70-year-old female patient with severe aortic stenosis who underwent TAVI using a 26-mm CoreValve Evolut Pro (Medtronic, Dublin, Ireland). Although the valve was implanted successfully, she experienced hypotension with intermittent ST elevations and had a cardiac arrest shortly after, requiring Advanced Cardiovascular Life Support (ACLS). An aortogram showed sealing of the sinotubular junction (STJ) by CoreValve, without coronary flow. CoreValve was then snared and repositioned in the ascending aorta recovering coronary flow and cardiac pulsatility. A second TAVI was performed and an Edwards 20 mm Sapiens 3 valve (Edwards Lifesciences, Irvine, CA, USA) was implanted as standard procedure.
- Open Access
- 1 June 2021
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 14, 2239-2248
Complete Revascularization of Stable STEMI Patients Offers a Significant Benefit if Done During the Index PCI, but Not if It’s Done as a Staged Procedure
Background: Complete revascularization (CR) of hemodynamically stable STEMI improves outcomes when compared to culprit-only PCI. However, the optimal timing for CR (CR during index PCI [iCR] versus staged PCI [sCR]) is unknown. sCR is defined as revascularization of non-culprit lesions not done during the index procedure (mean 31.5± 24.6 days after STEMI). Our goal was to determine whether iCR was the superior strategy when compared to sCR. Methods: A systematic review of Medline, Cochrane, and Embase was performed for RCTs reporting outcomes of stable STEMI patients who had undergone CR. Only RCTs with a clearly defined timing of CR, for the classification into iCR and sCR, and a follow-up of at least 12 months were included. Seven RCTs comprising 6647 patients (mean age:62.9± 1.4 years, male sex:79.4%) met these criteria and were included. Results: After a mean follow-up of 25.1± 9.4 months, iCR was associated with a significant reduction in cardiovascular mortality (risk ratio [RR] 0.48, 95% confidence interval [CI] 0.26– 0.90, p=0.02, relative risk reduction [RRR] 52%) and non-fatal reinfarctions (RR 0.42, 95% CI 0.25– 0.70, p=0.001, RRR: 58%). sCR showed a significant reduction in non-fatal reinfarctions only (RR 0.68, 95% CI 0.54– 0.85, p=0.0008, RRR: 32%). There was no difference in the safety outcome of contrast-induced nephropathy between groups. Conclusion: iCR of stable STEMI patients is associated with a significant reduction in cardiovascular death and a trend towards reduction in all-cause mortality. These benefits are not seen in sCR. Both strategies are associated with a reduction in non-fatal reinfarctions.
- 1 June 2021
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 14, 2239-2248
Open AccessComplete Revascularization of Stable STEMI Patients Offers a Significant Benefit if Done During the Index PCI, but Not if It’s Done as a Staged Procedure
Background: Complete revascularization (CR) of hemodynamically stable STEMI improves outcomes when compared to culprit-only PCI. However, the optimal timing for CR (CR during index PCI [iCR] versus staged PCI [sCR]) is unknown. sCR is defined as revascularization of non-culprit lesions not done during the index procedure (mean 31.5± 24.6 days after STEMI). Our goal was to determine whether iCR was the superior strategy when compared to sCR. Methods: A systematic review of Medline, Cochrane, and Embase was performed for RCTs reporting outcomes of stable STEMI patients who had undergone CR. Only RCTs with a clearly defined timing of CR, for the classification into iCR and sCR, and a follow-up of at least 12 months were included. Seven RCTs comprising 6647 patients (mean age:62.9± 1.4 years, male sex:79.4%) met these criteria and were included. Results: After a mean follow-up of 25.1± 9.4 months, iCR was associated with a significant reduction in cardiovascular mortality (risk ratio [RR] 0.48, 95% confidence interval [CI] 0.26– 0.90, p=0.02, relative risk reduction [RRR] 52%) and non-fatal reinfarctions (RR 0.42, 95% CI 0.25– 0.70, p=0.001, RRR: 58%). sCR showed a significant reduction in non-fatal reinfarctions only (RR 0.68, 95% CI 0.54– 0.85, p=0.0008, RRR: 32%). There was no difference in the safety outcome of contrast-induced nephropathy between groups. Conclusion: iCR of stable STEMI patients is associated with a significant reduction in cardiovascular death and a trend towards reduction in all-cause mortality. These benefits are not seen in sCR. Both strategies are associated with a reduction in non-fatal reinfarctions.
- Open Access
- 1 June 2020
- Published by Elsevier in JACC: Case Reports
- Vol. 2 (7) , 1009-1013
An Overlap Presentation of Pericardial Decompression Syndrome and Stress Cardiomyopathy Following Therapeutic Pericardiocentesis
- 1 June 2020
- Published by Elsevier in JACC: Case Reports
- Vol. 2 (7) , 1009-1013
Open AccessAn Overlap Presentation of Pericardial Decompression Syndrome and Stress Cardiomyopathy Following Therapeutic Pericardiocentesis
- 30 June 2019
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (8) , 1250-1257
Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: A systematic review and meta‐analysis
Aims: We sought to examine whether continuing oral anticoagulation (OAC) after catheter ablation (CA) for atrial fibrillation (AF) is associated with improved outcomes. OAC reduces morbidity and mortality in patients with AF. However, the continuation of OAC following the blanking period of CA is controversial due to conflicting published data.Methods: A systematic review of Medline, Cochrane, and Embase was performed for studies comparing patients who were continued on OAC (ON‐OAC) vs those in which OAC was discontinued (OFF‐OAC). CHA2DS2 VASc score had to be available for the classification of patients into high‐ or low‐risk cohorts (CHA2DS2 VASc ≥ 2 and ≤ 1, respectively). The primary efficacy outcome was thromboembolic events (TE). Intracranial hemorrhage (ICH) was the primary safety outcome.Results: Five studies comprising 3956 patients were included (mean age, 61.1 ± 2.9 years; 72.4% male, CHA2DS2 VASc ≤ 1 50.1%; CHA2DS2 VASc ≥ 2 49.9%). After a mean follow‐up of 39.6 ± 11.7 months, OAC‐continuation was associated with a significant decrease in risk of TE in the high‐risk cohort (CHA2DS2 VASc ≥ 2) (risk ratio [RR] 0.41, 95% confidence interval [CI] 0.21‐0.82, P = .01) with a RR reduction of 59%. ICH was significantly higher in the ON‐OAC group (RR, 5.78; 95% CI, 1.33‐25.08; P = .02). No significant benefit was observed in the low‐risk cohort ON‐OAC after the blanking period.Conclusion: Continuation of OAC after CA of AF with CHA2DS2 VASc ≥ 2 is associated with a significant decreased TE risk and a favorable net clinical benefit in spite of ICH being significantly increased in the ON‐OAC group. Continued OAC offers no benefit with CHA2DS2VASC ≤ 1.
- 30 June 2019
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (8) , 1250-1257
Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: A systematic review and meta‐analysis
Aims: We sought to examine whether continuing oral anticoagulation (OAC) after catheter ablation (CA) for atrial fibrillation (AF) is associated with improved outcomes. OAC reduces morbidity and mortality in patients with AF. However, the continuation of OAC following the blanking period of CA is controversial due to conflicting published data.Methods: A systematic review of Medline, Cochrane, and Embase was performed for studies comparing patients who were continued on OAC (ON‐OAC) vs those in which OAC was discontinued (OFF‐OAC). CHA2DS2 VASc score had to be available for the classification of patients into high‐ or low‐risk cohorts (CHA2DS2 VASc ≥ 2 and ≤ 1, respectively). The primary efficacy outcome was thromboembolic events (TE). Intracranial hemorrhage (ICH) was the primary safety outcome.Results: Five studies comprising 3956 patients were included (mean age, 61.1 ± 2.9 years; 72.4% male, CHA2DS2 VASc ≤ 1 50.1%; CHA2DS2 VASc ≥ 2 49.9%). After a mean follow‐up of 39.6 ± 11.7 months, OAC‐continuation was associated with a significant decrease in risk of TE in the high‐risk cohort (CHA2DS2 VASc ≥ 2) (risk ratio [RR] 0.41, 95% confidence interval [CI] 0.21‐0.82, P = .01) with a RR reduction of 59%. ICH was significantly higher in the ON‐OAC group (RR, 5.78; 95% CI, 1.33‐25.08; P = .02). No significant benefit was observed in the low‐risk cohort ON‐OAC after the blanking period.Conclusion: Continuation of OAC after CA of AF with CHA2DS2 VASc ≥ 2 is associated with a significant decreased TE risk and a favorable net clinical benefit in spite of ICH being significantly increased in the ON‐OAC group. Continued OAC offers no benefit with CHA2DS2VASC ≤ 1.
- Open Access
- 1 May 2019
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 5 (5) , 269-273
Segmental left atrial appendage electrical isolation to avoid left phrenic nerve damage
- 1 May 2019
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 5 (5) , 269-273
Open AccessSegmental left atrial appendage electrical isolation to avoid left phrenic nerve damage
- Open Access
- 14 August 2018
- Published by Juniper Publishers in Journal of Cardiology & Cardiovascular Therapy
- Vol. 11 (4) , 1-4
A Novel Approach to Extending DF-4 AICD Leads using A DF-4 Y Splitter/Adaptor as Preparation for Stereotactic Radiosurgery to The Chest - A Case Report
Scholarly articles on cardiology Journal of Cardiology & Cardiovascular Therapy is an Open Access, international peer reviewed journal launched from Juniper Publishers. Cardiology is a branch of medicine deals with the disorders of heart that keeps cardiologists up to date with advances in the diagnosis and treatment of cardiovascular diseases. This is an 80-year-old Hispanic male, former smoker with 30+ pack-years, COPD, ischemic cardiomyopathy with reduced Left Ventricular Ejection Fraction (LVEF) of 15-20% refractory to an appropriate trial of optimal medical therapy, requiring upgrade to Biventricular Implantable Cardioverter-Defibrillator (BIV-ICD) implantation. Five months after BIV-ICD implantation, the LVEF had improved to 55%. During routine lung cancer screening a left upper lobe mass measuring 1.5x1.1 cm was found. A biopsy was done, and further histology showed a spiculated squamous cell carcinoma.
- 14 August 2018
- Published by Juniper Publishers in Journal of Cardiology & Cardiovascular Therapy
- Vol. 11 (4) , 1-4
Open AccessA Novel Approach to Extending DF-4 AICD Leads using A DF-4 Y Splitter/Adaptor as Preparation for Stereotactic Radiosurgery to The Chest - A Case Report
Scholarly articles on cardiology Journal of Cardiology & Cardiovascular Therapy is an Open Access, international peer reviewed journal launched from Juniper Publishers. Cardiology is a branch of medicine deals with the disorders of heart that keeps cardiologists up to date with advances in the diagnosis and treatment of cardiovascular diseases. This is an 80-year-old Hispanic male, former smoker with 30+ pack-years, COPD, ischemic cardiomyopathy with reduced Left Ventricular Ejection Fraction (LVEF) of 15-20% refractory to an appropriate trial of optimal medical therapy, requiring upgrade to Biventricular Implantable Cardioverter-Defibrillator (BIV-ICD) implantation. Five months after BIV-ICD implantation, the LVEF had improved to 55%. During routine lung cancer screening a left upper lobe mass measuring 1.5x1.1 cm was found. A biopsy was done, and further histology showed a spiculated squamous cell carcinoma.